Completed

NCT Number: NCT01911676

Translational Neuroscience Optimization of GlyT1 Inhibitor

This is a Phase II, randomized, double-blind, placebo-controlled, cross-over POC study of stable patients with Schizophrenia or Schizoaffective disorder. The primary objective of this study is to test the efficacy of treatment with one of two does of a glycine transporter inhibitor (GlyT1I) combined with cognitive remediation to enhavce cognitive function. Subjects will be randomized to one of two doses of the glycine transporter inhibitor (GlyT1I) and placebo twice daily in addition to their antipsychotic medication for 2 treatment periods, each lasting a minimum of 5 weeks. Treatment periods will be separated by a washout period lasting approximately 3 weeks.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cognitive Impairments Associated With Schizophrenia

Age range

21 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Connecticut Mental Health Center, New Haven, Connecticut, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

1) Males or females 21 to 65 years of age (inclusive).
2) Diagnosis of Schizophrenia or Schizoaffective Disorder
3) Able to provide written informed consent.
4) Only CYP2D6 extensive metabolizers.

Exclusion criteria

1) No ongoing acute medical issues
2) Clinically significant ECG abnormality
3) Blood donation within eight weeks of the start of the study
4) Current treatment with Clozapine

Treatment and study plan

PF-03463275

Drug

Placebo

Drug

Primary outcomes

Change in Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB)

Time frame: Change from baseline in cognitive measures at approximately 5 weeks. Mean scores were calculated per time point for each arm.

To test the efficacy of PF-03463275 on cognitive test performance specifically, the MCCB composite score was used. The MCCB consists of 10 tests and provides standard scores and percentiles for each of seven cognitive domains and an overall composite score. Domains assessed include: speed of processing, attention/vigilance, working memory (verbal and visual), verbal learning, visual learning, reasoning and problem solving, and social cognition. The MCCB overall composite score is presented as a T-score. The range of T-scores is between 0 to 100 with a mean of 50 and standard deviation of 10. Higher scores indicate better overall cognitive functioning.

Secondary outcomes

Alteration in Symptom Domain Scores and Event Related Potentials (ERPs) With PF-03463275

Time frame: Change from Baseline at approximately 1 week

To determine whether PF-03463275 impacts symptom domain scores and visual event related potentials (ERPs), analogous to long-term potentiation (LTP) with PF-03463275 treatment. A more positive value reflects a better outcome - there is no established range to report. A Z-score of 0 indicates the mean score. A positive z-score indicates the mean is higher than average.

Sponsors and collaborators

Lead sponsor

Yale University

Other

Collaborators

National Center for Advancing Translational Sciences (NCATS)

Registry information

Acronym: NCATS

Important dates

Study start: 2013
Primary completion: 2018
Study completion: 2018
First posted: Jul 30, 2013
Registry last updated: Aug 19, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.